GlassScriptPhysician profile
Edgar B Bassig
NPI 1205891306
$10,861.93
in general payments reported to CMS, 2019-2025
52 companies · $1,704 in 2025
The $1,704 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,249 · 2020: $2,060 · 2021: $1,991 · 2022: $586 · 2023: $866 · 2024: $1,407 · 2025: $1,704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,879 · Education: $96.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,879.30 |
| Education | $96.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,599.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,155.20 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $892.44 | 2019-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $735.24 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $699.47 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $694.76 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $632.55 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $583.34 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $529.32 | 2020-2025 | Xifaxan |
| Astellas Pharma US INC | $261.84 | 2019-2024 | Veozah |
| Janssen Pharmaceuticals, INC | $247.93 | 2019-2021 | |
| Amarin Pharma, INC. | $230.27 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $183.20 | 2023-2025 | |
| Mannkind Corporation | $168.70 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $165.40 | 2019-2023 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edgar Bassig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.